Evidence map›Paper›PMID 34238629›Full record

ArticleJournal of substance abuse treatment2022

Mobile low-threshold buprenorphine integrated with infectious disease services.

Amanda Rosecrans, Robert Harris, Ronald E Saxton, Margaret Cotterell, Meredith Zoltick, Catherine Willman, Ingrid Blackwell, Joy Bell, Darryl Hayes, Brian Weir and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of substance abuse treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 43 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Multisite Mobile Addiction Services: Four-Year Outcomes.International journal of environmental research and public health · 2026
    Article
  5. Article
  6. Article
  7. Mobile addiction treatment units: a narrative review.Addiction science & clinical practice · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Amanda RosecransJohns Hopkins University School of Medicine, 600 N. Wolfe St., Baltimore, MD, USA; Baltimore City Health Department, 1200 E. Fayette St., Baltimore, MD, USA. Electronic address: arosecr1@jhmi.edu.
Robert HarrisJohns Hopkins University School of Medicine, 600 N. Wolfe St., Baltimore, MD, USA; Baltimore City Health Department, 1200 E. Fayette St., Baltimore, MD, USA.
Ronald E SaxtonJohns Hopkins University School of Medicine, 600 N. Wolfe St., Baltimore, MD, USA.
Margaret CotterellJohns Hopkins University School of Medicine, 600 N. Wolfe St., Baltimore, MD, USA; Baltimore City Health Department, 1200 E. Fayette St., Baltimore, MD, USA.
Meredith ZoltickJohns Hopkins University School of Medicine, 600 N. Wolfe St., Baltimore, MD, USA; Baltimore City Health Department, 1200 E. Fayette St., Baltimore, MD, USA.
Catherine WillmanJohns Hopkins University School of Medicine, 600 N. Wolfe St., Baltimore, MD, USA; Baltimore City Health Department, 1200 E. Fayette St., Baltimore, MD, USA.
Ingrid BlackwellJohns Hopkins University School of Medicine, 600 N. Wolfe St., Baltimore, MD, USA; Baltimore City Health Department, 1200 E. Fayette St., Baltimore, MD, USA.
Joy BellJohns Hopkins University School of Medicine, 600 N. Wolfe St., Baltimore, MD, USA; Baltimore City Health Department, 1200 E. Fayette St., Baltimore, MD, USA.
Darryl HayesJohns Hopkins University School of Medicine, 600 N. Wolfe St., Baltimore, MD, USA; Baltimore City Health Department, 1200 E. Fayette St., Baltimore, MD, USA.
Brian WeirJohns Hopkins Bloomberg School of Public Health, 615 N. Wolfe, Baltimore, MD, USA.
Susan ShermanJohns Hopkins Bloomberg School of Public Health, 615 N. Wolfe, Baltimore, MD, USA.
Gregory M LucasJohns Hopkins University School of Medicine, 600 N. Wolfe St., Baltimore, MD, USA.
Adena GreenbaumBaltimore City Health Department, 1200 E. Fayette St., Baltimore, MD, USA.
Kathleen R PageJohns Hopkins University School of Medicine, 600 N. Wolfe St., Baltimore, MD, USA.
Johns Hopkins University · US

Funding

Juntos (Together): A community led approach to enhance to Covid-19 testing among vulnerable LatinosR01DA045556 · NIDA · JOHNS HOPKINS UNIVERSITY · PI LUCAS, GREGORY M, PAGE, KATHLEEN R · 2017 to 2022
$6.8M
Treatment outcomes and comorbidity in HIV-infected IDUK24DA035684 · NIDA · JOHNS HOPKINS UNIVERSITY · PI LUCAS, GREGORY M · 2014 to 2024
$1.5M
Mentoring in Community-engaged Research to Promote Outcomes for LatinosK24NR020508 · NINR · JOHNS HOPKINS UNIVERSITY · PI Kathleen R Page · 2022 to 2026
$942k
NIDA NIH HHS K24 DA035684NIDA NIH HHS R01 DA045556NINR NIH HHS K24 NR020508
6 · The paper itself

Abstract

introductionIn 2018, the Baltimore City Health Department launched a mobile clinic called Healthcare on The Spot, which offers low-threshold buprenorphine services integrated with health care services to meet the needs of people who use drugs. In addition to buprenorphine management, The Spot offers testing and treatment for hepatitis C, sexually transmitted infections, and HIV, as well as pre-exposure prophylaxis for HIV, wound care, vaccinations, naloxone distribution, and case management. METHODS AND MATERIALS: This cohort analysis includes clinical service data from the first 15 months of The Spot mobile clinic, from September 4, 2018, to November 23, 2019. The Spot co-located with the Baltimore syringe services program in five locations across the city. Descriptive data are provided for patient demographics and services provided, as well as percent of patients retained in buprenorphine treatment at one and three months. Logistic regression identified factors associated with retention at three months.

resultsThe Spot mobile clinic provided services to 569 individuals from September 4, 2018, to November 23, 2019, including prescribing buprenorphine to 73.8% and testing to more than 70% for at least one infectious disease. Patients receiving a prescription for buprenorphine were more likely to be tested for HIV, hepatitis C, and sexually transmitted infections, as well as receive treatment for hepatitis C and preventive services including vaccination and naloxone distribution. The Spot initiated HIV treatment for four patients and HIV pre-exposure prophylaxis for twelve patients. More than 32% of patients had hepatitis C; nineteen of these patients initiated treatment for hepatitis C with eight having a documented cure. Buprenorphine treatment retention was 56.0% at one month and 26.2% at three months. Patients who were Black or receiving treatment for hepatitis C were more likely to be retained in buprenorphine treatment at three months.

conclusionsIncreasing access to integrated medical services and drug treatment through low-threshold, community-based models of care can be an effective tool for addressing the effects of drug use.

Indexed as

BuprenorphineHepatitis COpioid-Related DisordersBuprenorphine, Naloxone Drug CombinationHumansMobile Health UnitsNaloxoneOpiate Substitution TreatmentBuprenorphineBuprenorphine, Naloxone Drug CombinationNaloxoneBuprenorphineHepatitis CIntegrated careLow-thresholdMobileOpioid use disorder

Identifiers

PMID34238629
PMCPMC8702567
OpenAlexW3174846920

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.